YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
Exagen Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Achieve…
Key Points Interested in Exagen Inc.? Here are five stocks we like better. Record revenue and improved profitability: Exagen's second-quarter revenue rose 16% year over year to $19.9 million, while its adjusted EBITDA loss narrowed to just…
Blood test ©Adobe Stock Images Exagen (NASDAQ:XGN) delivered record quarterly revenue, narrowed losses, improved adjusted EBITDA, and increased its full-year revenue outlook as demand for its autoimmune testing portfolio continued to grow.…
Exagen Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Perform…
Earnings Call Insights: Exagen (XGN) Q1 2026 MANAGEMENT VIEW * “We reported record first quarter revenue of $17.3 million, up 12% year-over-year,” and “gross margin was 59% and adjusted EBITDA loss reduced to $2.2 million,” CEO John Aballi…
Exagen logo Key Points Interested in Exagen Inc.? Here are five stocks we like better. Exagen posted record Q1 revenue of $17.3 million, up 12% year over year, and reaffirmed its full-year 2026 revenue guidance of $70 million to $73 millio…
medical research 9 ©George Hodan Exagen delivered record first-quarter revenue and improved adjusted EBITDA metrics as the autoimmune diagnostics company continued expanding adoption of its AVISE CTD testing platform. Key Investor Takeaway…
AtriCure (ATRC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarte…
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.81 per share a year ago. These figures are adjusted for non-recurring items.…
Exagen Inc. (NASDAQ:XGN) earns a spot on our list of the best penny stocks set to explode.Does Exagen (XGN)’s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode? As of April 8, 2026, analyst sentiment toward Exagen…
Earnings Call Insights: Exagen Inc. (XGN) Q4 2025 MANAGEMENT VIEW * CEO John Aballi emphasized Exagen’s commitment to addressing diagnostic delays in autoimmune diseases, stating the company is “working to own the entire space, providing m…
Exagen logo Key Points Exagen closed 2025 with record revenue of $66.6 million and 137,000 AVISE CTD tests, driven by higher testing volume (Q4 volume +22% YoY) and expanded sales coverage to 45 territories. Trailing 12‑month ASP increased…
Quant rankings for the upcoming earnings calendar show strength in materials and consumer-related names, while several health care, technology, and communication services companies appear among the weakest-scoring stocks. Silver miner Avin…
Agilent Technologies (A) came out with quarterly earnings of $1.36 per share, missing the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring it…
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025…
Earnings Call Insights: Exagen Inc. (XGN) Q3 2025 MANAGEMENT VIEW * CEO John Aballi reported, "Q3 was the strongest quarter in Exagen's history, driven by robust volume growth and continued execution across our commercial, scientific and o…
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, A…
CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday…
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 B…
CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord…
Earnings Call Insights: Exagen Inc. (XGN) Q2 2025 MANAGEMENT VIEW * John Aballi, CEO, stated that "Q2 revenue came in at $17.2 million, representing 14% year-over-year growth and the highest quarterly revenue in company history." He highli…
Exagen Inc. (market cap: $169 million) reported its second-quarter 2025 earnings, revealing a revenue of $17.2 million, which surpassed forecasts and marked the highest quarterly revenue in the company’s history. Despite this achievement,…
Exagen Inc (NASDAQ:XGN [https://www.chartmill.com/stock/quote/XGN/profile]), a commercial-stage diagnostics company specializing in autoimmune testing solutions, reported its second-quarter 2025 financial results, surpassing revenue expect…
Investing.com - Exagen (NASDAQ: XGN) reported second quarter EPS of $-0.210, $0.06 worse than the analyst estimate of $-0.150. Revenue for the quarter came in at $17.2M versus the consensus estimate of $16.23M. Exagen’s stock price closed…
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish thes…
Exagen Inc. CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective…
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, Jul…
* Exagen (NASDAQ:XGN [https://seekingalpha.com/symbol/XGN]) is registering up to 1.15M shares of common stock for resale by Perceptive Credit Holdings or its affiliates. * The shares are issuable upon exercise of a warrant granted under a…
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a publi…
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025.…
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: BTIG at Snowbird: Med…
SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. Recognized total revenue of…
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement. E…
SAN DIEGO, California, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health…
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, after the market close on Monday, November…